RBI 5000
Alternative Names: COVID-19 vaccine- Immunomic Therapeutics/Replicate Bioscience; RBI-5000Latest Information Update: 29 Jul 2024
At a glance
- Originator Immunomic Therapeutics; Replicate Bioscience
 - Class RNA vaccines; Viral vaccines
 - Mechanism of Action Immunostimulants
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity No
 
Highest Development Phases
- Preclinical Epstein-Barr virus infections
 - Discontinued COVID 2019 infections
 
Most Recent Events
- 29 Jul 2024 Discontinued for COVID-2019 infections in USA (Parenteral) (Replicate Biosciences pipeline, July 2024)
 - 29 Jul 2024 Preclinical trials in Epstein-Barr virus infections (Prevention) in USA (Parenteral) (Replicate Biosciences pipeline, July 2024)
 - 28 Jul 2024 No recent reports of development identified for research development in COVID-2019-infections in USA (Parenteral)